Research theme for competitive and other funds (6)：
2020 - 2022 マルチキナーゼ阻害薬による新規骨肉腫治療の開発
2021 - 2022 Clinical and pathological analysis of factors affecting chemoresistance in osteosarcoma patients
2021 - 2022 Analysis of effects of multikinase inhibitors on osteosarcoma
2019 - 2019 肉腫の転移浸潤メカニズムの解明と新規治療の開発
2017 - 2018 Graduate-Level Research Exchange
2017 - 2018 軟骨肉腫に対するPPARγを標的にした抗腫瘍効果の解析
Show all
Papers (141)：
Sei Morinaga, Qinghong Han, Yutaro Kubota, Kohei Mizuta, Byung Mo Kang, Motokazu Sato, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, et al. DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts. Anticancer research. 2024. 44. 6. 2359-2367
Takashi Higuchi, Atsushi Taninaka, Rikuto Yoshimizu, Katsuhiro Hayashi, Shinji Miwa, Norio Yamamoto, Hiroyuki Tsuchiya, Satoru Demura. Intraoperative Fracture during the Insertion of Advanced Locking Screws (T2 Alpha Femur Retrograde Intramedullary Nailing System): Report of Two Cases and Identifying Causes and Prevention. Journal of clinical medicine. 2024. 13. 8
SEI MORINAGA, QINGHONG HAN, YUTARO KUBOTA, KOHEI MIZUTA, BYUNG MO KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, et al. Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts. Anticancer Research. 2024. 44. 3. 921-928
TAKASHI HIGUCHI, NORIO YAMAMOTO, KATSUHIRO HAYASHI, SHINJI MIWA, KENTARO IGARASHI, HIROYUKI TSUCHIYA, ROBERT M. HOFFMAN. High Clinical Concordance of Drug Resistance in Patient-derived Orthotopic Xenograft (PDOX) Mouse Models: First Step to Validated Precise Individualized Cancer Chemotherapy. Anticancer Research. 2023. 43. 10. 4277-4284
Yohei Asano, Norio Yamamoto, Satoru Demura, Katsuhiro Hayashi, Akihiko Takeuchi, Satoshi Kato, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Yuta Taniguchi, et al. Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis. Cancer medicine. 2023. 12. 11. 12425-12437
- 2018 Kanazawa University Graduate School of Medical Science
- 2009 Kanazawa University
Professional career (1)：
医学博士 (金沢大学大学院医薬保健学総合研究科)
Work history (9)：
2022/04 - 現在 Kanazawa Red Cross Hospital Orthopaedic Surgery Manager
2020/04 - 2022/03 Japanese Red Cross Kanazawa Hospital Orahopaedic Surgery vice manager
2020/01 - 2020/03 Kanazawa University Hospital Department of Orthopaedic Surgery Medical staff
2017/11 - 2019/12 University of California San Diego (UCSD) Department of Surgery Visiting scholar
2013/10 - 2017/10 金沢大学付属病院 整形外科 医員
2012/04 - 2013/09 富山県済生会高岡病院 整形外科 医員
2011/10 - 2012/09 福井総合病院 整形外科 医員
2011/04 - 2011/09 金沢大学付属病院 整形外科 医員
2009/04 - 2011/03 Tokyo Women's Medical University Medical Center East
Show all
Awards (4)：
2021/06 - Kanazawa University Juzen Medical Society 1st Juzen Medical Encouragement Award Mechanism of metastasis and new treatment development in sarcoma
2018/10 - 39th Société Internationale de Chirurgie Orthopédique et de Traumatologie(SICOT)Orthopaedic World Congress The Lester Lowe SICOT Award
2018/09 - Kanazawa University President Award Anti-tumor effects of a non-steroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression
2017/10 - Society Encouragement Award
Association Membership(s) (5)：
International Society Of Limb Salvage
, Société Internationale de Chirurgie Orthopédique et de Traumatologie International Society of Orthopaedic Surgery and Traumatology
, JAPAN SOCIETY OF CLINICAL ONCOLOGY
, The Central Japan Association of Orthopaedic Surgery and Traumatology
, THE JAPANESE ORTHOPAEDIC ASSOCIATION
